Key clinical point: The combination of a CDK4/6 inhibitor and an aromatase inhibitor shows potential as an alternative to standard multidrug neoadjuvant chemotherapy.

Major finding: Neoadjuvant therapy with ribociclib plus letrozole was as effective as standard multiagent chemotherapy for downstaging high-risk luminal B breast cancer, but with markedly less toxicity.

Study details: This phase 2 multicenter, open-label randomized trial included 106 postmenopausal women with hormone receptor–positive and HER2-negative high-risk luminal B subtype breast cancer.

Disclosures: The SOLTI-1402/CORALLEEN trial was sponsored by Novartis, the Breast Cancer Research Foundation, the American Association for Cancer Research, and the Breast Cancer Now Career Catalyst. The presenter reported serving as a consultant to Novartis, Roche, and MSD.